NPM1 and acute myeloid leukemia: The VINCENT trial has the potential to significantly advance treatment paradigms for NPM1-mutated AML by providing comprehensive prospective data comparing VEN/AZA to SOC, addressing both efficacy and patient-centered outcomes.